Occam Places Jim Burns as CEO of Ensoma

Occam Places Jim Burns as CEO of Ensoma

Ensoma, a 5AM and F-Prime investment, is a genomic medicines company advancing the future of medicine through precision one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system.


Prior to joining Ensoma, Jim was CEO of Locanabio, a company focused on developing genetic medicines for neuromuscular and neurodegenerative diseases. Before that, he was CEO of Casebia Therapeutics, which is not part of CRISPR Therapeutics.  Burns spent the bulk of his career at Genzyme and Sanofi, where he held several leadership roles with increasing responsibility, including North America site head for R&D, where he coordinated R&D operations across key therapeutic areas.


Jim earned a Bachelor of Science degree in biology from Purdue University and a Master of Science and doctoral degree in bioengineering from the University of Illinois-Chicago. His thesis work focused on drug delivery.  He was a postdoctoral researcher at the University of Florida after his graduate studies.

About Occam Global

Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.